Clinical trial

Nilotinib in Parkinson's Disease

NCT03205488

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2017-10-16

PhasePHASE2

Study timeline

Study start (actual)2017-10-16Date precision: day

Registry last updated2020-07-22

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Parkinson Diseaseverified · MONDO: Parkinson disease

Interventions

Cohort 1:Nilotinib Oral Capsules (150mg or 300mg)DRUG

Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1)DRUG

Sponsors & collaborators

Northwestern Universitylead sponsor

University of Rochestercollaborator

University of Iowacollaborator

Michael J. Fox Foundation for Parkinson's Researchcollaborator

Mapped research locations

New YorkNew York, United States1 HoustonTexas, United States1 BostonMassachusetts, United States1 ChicagoIllinois, United States1 PhiladelphiaPennsylvania, United States1 BaltimoreMaryland, United States1 ClevelandOhio, United States1 BirminghamAlabama, United States1 CincinnatiOhio, United States1 TampaFlorida, United States1 PortlandOregon, United States1 DurhamNorth Carolina, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03205488 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.